Cargando…

New Dominant-Negative IL6ST Variants Expand the Immunological and Clinical Spectrum of GP130-Dependent Hyper-IgE Syndrome

Patients with autosomal dominant (AD) hyper-IgE syndrome (HIES) suffer from a constellation of manifestations including recurrent bacterial and fungal infections, severe atopy, and skeletal abnormalities. This condition is typically caused by monoallelic dominant-negative (DN) STAT3 variants. In 202...

Descripción completa

Detalles Bibliográficos
Autores principales: Arlabosse, Tiphaine, Materna, Marie, Riccio, Orbicia, Schnider, Caroline, Angelini, Federica, Perreau, Matthieu, Rochat, Isabelle, Superti-Furga, Andrea, Campos-Xavier, Belinda, Héritier, Sébastien, Pereira, Anaïs, Deswarte, Caroline, Lévy, Romain, Distefano, Marco, Bustamante, Jacinta, Roelens, Marie, Borie, Raphaël, Le Brun, Mathilde, Crestani, Bruno, Casanova, Jean-Laurent, Puel, Anne, Hofer, Michaël, Fieschi, Claire, Theodoropoulou, Katerina, Béziat, Vivien, Candotti, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499999/
https://www.ncbi.nlm.nih.gov/pubmed/37273120
http://dx.doi.org/10.1007/s10875-023-01517-4
_version_ 1785105831821312000
author Arlabosse, Tiphaine
Materna, Marie
Riccio, Orbicia
Schnider, Caroline
Angelini, Federica
Perreau, Matthieu
Rochat, Isabelle
Superti-Furga, Andrea
Campos-Xavier, Belinda
Héritier, Sébastien
Pereira, Anaïs
Deswarte, Caroline
Lévy, Romain
Distefano, Marco
Bustamante, Jacinta
Roelens, Marie
Borie, Raphaël
Le Brun, Mathilde
Crestani, Bruno
Casanova, Jean-Laurent
Puel, Anne
Hofer, Michaël
Fieschi, Claire
Theodoropoulou, Katerina
Béziat, Vivien
Candotti, Fabio
author_facet Arlabosse, Tiphaine
Materna, Marie
Riccio, Orbicia
Schnider, Caroline
Angelini, Federica
Perreau, Matthieu
Rochat, Isabelle
Superti-Furga, Andrea
Campos-Xavier, Belinda
Héritier, Sébastien
Pereira, Anaïs
Deswarte, Caroline
Lévy, Romain
Distefano, Marco
Bustamante, Jacinta
Roelens, Marie
Borie, Raphaël
Le Brun, Mathilde
Crestani, Bruno
Casanova, Jean-Laurent
Puel, Anne
Hofer, Michaël
Fieschi, Claire
Theodoropoulou, Katerina
Béziat, Vivien
Candotti, Fabio
author_sort Arlabosse, Tiphaine
collection PubMed
description Patients with autosomal dominant (AD) hyper-IgE syndrome (HIES) suffer from a constellation of manifestations including recurrent bacterial and fungal infections, severe atopy, and skeletal abnormalities. This condition is typically caused by monoallelic dominant-negative (DN) STAT3 variants. In 2020, we described 12 patients from eight kindreds with DN IL6ST variants resulting in a new form of AD HIES. These variants encoded truncated GP130 receptors, with intact extracellular and transmembrane domains, but lacking the intracellular recycling motif and the four STAT3-binding residues, resulting in an inability to recycle and activate STAT3. We report here two new DN variants of IL6ST in three unrelated families with HIES-AD. The biochemical and clinical impacts of these variants are different from those of the previously reported variants. The p.(Ser731Valfs*8) variant, identified in seven patients from two families, lacks the recycling motif and all the STAT3-binding residues, but its levels on the cell surface are only slightly increased and it underlies mild biological phenotypes with variable clinical expressivity. The p.(Arg768*) variant, identified in a single patient, lacks the recycling motif and the three most distal STAT3-binding residues. This variant accumulates at the cell surface and underlies severe biological and clinical phenotypes. The p.(Ser731Valfs*8) variant shows that a DN GP130 expressed at near normal levels on the cell surface can underlie heterogeneous clinical presentations, ranging from mild to severe. The p.(Arg768*) variant demonstrates that a truncated GP130 protein retaining one STAT3-binding residue can underlie severe HIES. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10875-023-01517-4.
format Online
Article
Text
id pubmed-10499999
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-104999992023-09-15 New Dominant-Negative IL6ST Variants Expand the Immunological and Clinical Spectrum of GP130-Dependent Hyper-IgE Syndrome Arlabosse, Tiphaine Materna, Marie Riccio, Orbicia Schnider, Caroline Angelini, Federica Perreau, Matthieu Rochat, Isabelle Superti-Furga, Andrea Campos-Xavier, Belinda Héritier, Sébastien Pereira, Anaïs Deswarte, Caroline Lévy, Romain Distefano, Marco Bustamante, Jacinta Roelens, Marie Borie, Raphaël Le Brun, Mathilde Crestani, Bruno Casanova, Jean-Laurent Puel, Anne Hofer, Michaël Fieschi, Claire Theodoropoulou, Katerina Béziat, Vivien Candotti, Fabio J Clin Immunol Original Article Patients with autosomal dominant (AD) hyper-IgE syndrome (HIES) suffer from a constellation of manifestations including recurrent bacterial and fungal infections, severe atopy, and skeletal abnormalities. This condition is typically caused by monoallelic dominant-negative (DN) STAT3 variants. In 2020, we described 12 patients from eight kindreds with DN IL6ST variants resulting in a new form of AD HIES. These variants encoded truncated GP130 receptors, with intact extracellular and transmembrane domains, but lacking the intracellular recycling motif and the four STAT3-binding residues, resulting in an inability to recycle and activate STAT3. We report here two new DN variants of IL6ST in three unrelated families with HIES-AD. The biochemical and clinical impacts of these variants are different from those of the previously reported variants. The p.(Ser731Valfs*8) variant, identified in seven patients from two families, lacks the recycling motif and all the STAT3-binding residues, but its levels on the cell surface are only slightly increased and it underlies mild biological phenotypes with variable clinical expressivity. The p.(Arg768*) variant, identified in a single patient, lacks the recycling motif and the three most distal STAT3-binding residues. This variant accumulates at the cell surface and underlies severe biological and clinical phenotypes. The p.(Ser731Valfs*8) variant shows that a DN GP130 expressed at near normal levels on the cell surface can underlie heterogeneous clinical presentations, ranging from mild to severe. The p.(Arg768*) variant demonstrates that a truncated GP130 protein retaining one STAT3-binding residue can underlie severe HIES. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10875-023-01517-4. Springer US 2023-06-05 2023 /pmc/articles/PMC10499999/ /pubmed/37273120 http://dx.doi.org/10.1007/s10875-023-01517-4 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Arlabosse, Tiphaine
Materna, Marie
Riccio, Orbicia
Schnider, Caroline
Angelini, Federica
Perreau, Matthieu
Rochat, Isabelle
Superti-Furga, Andrea
Campos-Xavier, Belinda
Héritier, Sébastien
Pereira, Anaïs
Deswarte, Caroline
Lévy, Romain
Distefano, Marco
Bustamante, Jacinta
Roelens, Marie
Borie, Raphaël
Le Brun, Mathilde
Crestani, Bruno
Casanova, Jean-Laurent
Puel, Anne
Hofer, Michaël
Fieschi, Claire
Theodoropoulou, Katerina
Béziat, Vivien
Candotti, Fabio
New Dominant-Negative IL6ST Variants Expand the Immunological and Clinical Spectrum of GP130-Dependent Hyper-IgE Syndrome
title New Dominant-Negative IL6ST Variants Expand the Immunological and Clinical Spectrum of GP130-Dependent Hyper-IgE Syndrome
title_full New Dominant-Negative IL6ST Variants Expand the Immunological and Clinical Spectrum of GP130-Dependent Hyper-IgE Syndrome
title_fullStr New Dominant-Negative IL6ST Variants Expand the Immunological and Clinical Spectrum of GP130-Dependent Hyper-IgE Syndrome
title_full_unstemmed New Dominant-Negative IL6ST Variants Expand the Immunological and Clinical Spectrum of GP130-Dependent Hyper-IgE Syndrome
title_short New Dominant-Negative IL6ST Variants Expand the Immunological and Clinical Spectrum of GP130-Dependent Hyper-IgE Syndrome
title_sort new dominant-negative il6st variants expand the immunological and clinical spectrum of gp130-dependent hyper-ige syndrome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499999/
https://www.ncbi.nlm.nih.gov/pubmed/37273120
http://dx.doi.org/10.1007/s10875-023-01517-4
work_keys_str_mv AT arlabossetiphaine newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT maternamarie newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT riccioorbicia newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT schnidercaroline newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT angelinifederica newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT perreaumatthieu newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT rochatisabelle newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT supertifurgaandrea newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT camposxavierbelinda newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT heritiersebastien newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT pereiraanais newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT deswartecaroline newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT levyromain newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT distefanomarco newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT bustamantejacinta newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT roelensmarie newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT borieraphael newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT lebrunmathilde newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT crestanibruno newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT casanovajeanlaurent newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT puelanne newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT hofermichael newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT fieschiclaire newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT theodoropouloukaterina newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT beziatvivien newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome
AT candottifabio newdominantnegativeil6stvariantsexpandtheimmunologicalandclinicalspectrumofgp130dependenthyperigesyndrome